CN116854817B - Nano antibody targeting eIF4E2, E3 ligase chimeric and application thereof in ISGylation activation - Google Patents
Nano antibody targeting eIF4E2, E3 ligase chimeric and application thereof in ISGylation activation Download PDFInfo
- Publication number
- CN116854817B CN116854817B CN202310843861.5A CN202310843861A CN116854817B CN 116854817 B CN116854817 B CN 116854817B CN 202310843861 A CN202310843861 A CN 202310843861A CN 116854817 B CN116854817 B CN 116854817B
- Authority
- CN
- China
- Prior art keywords
- eif4e2
- isgylation
- ligase
- activation
- hect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 title claims abstract description 40
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 title claims abstract description 40
- 230000008685 targeting Effects 0.000 title claims abstract description 22
- 230000006133 ISGylation Effects 0.000 title abstract description 44
- 230000004913 activation Effects 0.000 title abstract description 23
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims description 14
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 11
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 claims description 7
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 abstract description 29
- 230000006870 function Effects 0.000 abstract description 5
- 230000014621 translational initiation Effects 0.000 abstract description 5
- 108010044843 Peptide Initiation Factors Proteins 0.000 abstract description 4
- 102000005877 Peptide Initiation Factors Human genes 0.000 abstract description 4
- 238000002818 protein evolution Methods 0.000 abstract description 4
- 102000003960 Ligases Human genes 0.000 abstract description 3
- 108090000364 Ligases Proteins 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 abstract 1
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 description 38
- 238000012986 modification Methods 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 34
- 239000002158 endotoxin Substances 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 15
- 238000001514 detection method Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 230000005012 migration Effects 0.000 description 9
- 238000013508 migration Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 8
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 102100038509 E3 ubiquitin-protein ligase ARIH1 Human genes 0.000 description 5
- 101000808922 Homo sapiens E3 ubiquitin-protein ligase ARIH1 Proteins 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 5
- 102000044159 Ubiquitin Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000000749 co-immunoprecipitation Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 3
- 208000035217 Ring chromosome 1 syndrome Diseases 0.000 description 2
- 208000032825 Ring chromosome 2 syndrome Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009712 regulation of translation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000028391 RNA cap binding Human genes 0.000 description 1
- 108091000106 RNA cap binding Proteins 0.000 description 1
- 101710087750 Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a nano antibody targeting eIF4E2, an E3 ligase chimeric body and application thereof in ISGylation activation, wherein the nano antibody takes eukaryotic translation initiation factor eIF4E2 of hypoxia response as a target, nano antibodies Nb.30C7 and Nb.28E11 targeting eIF4E 2N-terminal and C-terminal are screened through a nano antibody yeast display library, and specific activation of eIF4E2 ISGlytion in cells is realized by constructing a nano antibody-E3 ligase chimeric body; the activation of the site-specific ISGylation is beneficial to revealing the functions of the ISGylation, and provides a new idea for the research of single-target ISGylation in the future.
Description
Technical Field
The invention belongs to the technical field of application of eukaryotic translation initiation factor eIF4E2, and particularly relates to a nano antibody targeting eIF4E2, an E3 ligase chimera and application thereof in ISGylation activation.
Background
Regulation of protein synthesis is important for cellular homeostasis, survival, differentiation, and many other functions. The protein synthesis process is "very expensive" and consumes a large portion of the energy of the cell. Therefore, the cells need to produce an appropriate amount of protein at the correct time and place (Hershey et al 2019). Translational control is a critical step in regulating protein expression, and abnormal translational regulation leads to the occurrence of many diseases. Eukaryotic translation initiation factor eIF4E (eukaryotic translation initiation factor E, eIF 4E) plays a critical role in the regulation of protein synthesis by recognizing the cap structure present 5' to eukaryotic mRNA to initiate cap-dependent translation. eIF4E2is a homologous protein to eIF4E and also modulates translation initiation by cap-dependent translation. eIF4E2is not expressed in high amounts, but is ubiquitously expressed in various tissues, and can form a plurality of regulatory complexes with different binding partners, thereby coping with different physiological environment regulation translations (Christie et al 2021). eIF4E2 undergoes ISG (international-stimulated gene) post-translational modification that enhances its cap binding capacity, thereby functioning as a translational inhibitor and thus inhibiting translation of certain viral mrnas (Okumura et al 2007). However, whether the modified eIF4E2 modulates certain physiological processes and is related to the occurrence and development of certain diseases is yet to be studied.
Like ubiquitination, the ubiquitin-like modified ISGylation modification is an important post-translational modification that is widely present in eukaryotes. Ubiquitin-like protein ISG15 undergoes covalent attachment to a target protein mediated by a cascade of specific E1 activating enzyme, E2 coupling enzyme and E3 ligase upon stimulation of cells by type I interferon or the like to effect modification of ISGylation (Villarroya-Belri et al 2017). ISGylation is closely related to the regulation of physiological processes and diseases such as protein translation, autophagy, innate immunity, neoplasms, stroke and the like (Mirzalieva et al 2022). Although the activation of ISGylation modification can be accomplished by drugs such as LPS or co-transformation of ISGylation modification system plasmids (including E1 activating enzyme, E2 binding enzyme, E3 ligase and ISG15 plasmids), these methods activate ISGylation as global and multi-target activation, which cannot be done if one wants to study the effect of ISGylation modification of a certain target alone. Therefore, we want to develop a novel E3 ligase through nanobody to target and activate ISGylation modification, thereby helping us to conduct relevant research on specific target ISGylation.
Disclosure of Invention
A first object of the present invention is to propose a nanobody targeting eIF4E2, which can specifically bind to eIF4E2 protein; the nano antibody targeting eIF4E2 comprises the amino acid sequence shown in SEQ ID NO: 2-12.
Further, the amino acid sequence of the nano antibody is SEQ ID NO:2 and/or SEQ ID NO:11.
a second object of the present invention is to provide a nucleotide sequence encoding the above nanobody; the nucleotide sequence.
A third object of the present invention is to provide an eIF4E2 ISGylation-modified E3 ligase chimera comprising the nanobody described above, and a linking domain fragment linked to the nanobody; the connecting domain fragment is a domain for catalyzing ISG15 to transfer to target protein; the chimera can utilize the high specificity and high affinity of the nanobody to realize the ISGylation activation specific to the target protein.
Further, in the E3 ligase chimeric, the enzyme is ISGlyation E3 ligase and/or ubiquitin E3 ligase.
Preferably, the isglytion E3 ligase is HERC5 and the ubiquitin E3 ligase is HHARI.
More preferably, the amino acid sequence of the nanobody is as shown in SEQ ID NO:11, said linking domain fragment is selected from the group consisting of isglytion E3 ligase.
A fourth object of the present invention is to provide an expression vector comprising the above E3 ligase chimera; the expression vector can realize ISGylation activation specific to target proteins by utilizing high specificity and high affinity of the chimeric body.
A fifth object of the present invention is to provide a cell transfected with the above expression vector; the high specificity and high affinity of the expression vector can be exerted in cells, and the specific ISGylation activation of the target protein can be completed.
The fifth object of the invention is to provide the application of the expression vector in eIF4E2 ISGlytion activation, which can realize specific ISGylation modification for activating eIF4E2 and provide a new guide for independently researching the effect of ISGylation modification of a certain target point.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a method for screening the nano antibody for recognizing eIF4E2, and realizes specific activation of eIF4E2 ISGlytion in cells by constructing a nano antibody-E3 ligase chimera, thereby providing a new method and thinking for relevant research of ISGlytion.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the results of screening for antibodies targeting eIF4E2 nanobodies using the yeast surface display technology of the invention. (A) Results of eIF4E 2C-terminal (28 library-eye) nanobody 3 in-turn sorting. Three rounds of antigen concentrations were 1. Mu.M, 100nM,1nM, respectively; quadrant Q2 is the double positive region; the X-axis represents the fluorescence signal of the APC channel corresponding to Alexa647 and the Y-axis represents the fluorescence signal of the FITC channel corresponding to the antigen moiety. (B) Results of the round robin sorting of eIF4E 2N-terminal (30 library-eye) nanobody 3. Three rounds of antigen concentrations were 500nM,50nM,1nM, respectively; quadrant Q2 is the double positive region; the X-axis represents the fluorescence signal of the APC channel corresponding to Alexa647 and the Y-axis represents the fluorescence signal of the FITC channel corresponding to the antigen moiety.
FIG. 2is a graph showing the results of the verification of eIF4E2ISGylation modification of the present invention. (A) site of modification of eIF4E2 by ISGylation. (B) LPS treatment activated eIF4E2ISGylation, si-eIF4E2 in 293T cells reduced modification. After 24h treatment of 293T cells with si-eIF4E2 or Scramble, LPS (10 Mm) was added for 6h, protein samples were collected and Western felt detection was performed using eIF4E2 antibody detection. (C) LPS treatment activated eIF4E2ISGylation, PROTAC-eIF4E2 in BT549 cells reduced modification. pcDNA3.1-Flag-PROTAC-30C7 and pcDNA3.1-Flag-RPOTAC-28E11 were transfected into BT549 cells for 48h, and then treated with LPS (10 Mm) for 6h, and protein samples were collected and subjected to Western bolt assay with eIF4E2 antibody assay.
FIG. 3 shows the principle and results related to targeting eIF4E2ISGylation modified E3 ligase chimera of the present invention. (A) The E3 ligase HERC5 and HHARI are schematic structural representations in which the HECT domain and the RING1-IBR-RING2 (RBR) domain are functional domains that deliver ISG15, respectively. (B) Overlap PCR was performed to link E3 ligase with nanobody. (C) chimera-mediated ISGylation mechanism. The chimera is specifically combined with the target protein through the nano antibody, and the positions of the E3 ligase and the target protein are spatially pulled up, so that ISGylation modification is specifically activated. (D) Chimeric HECT-30C7 may be more effective in activating eIF4E2 ISGylation. 4 sets of chimeras (pcDNA3.1-HA-HECT-30C 7, pcDNA3.1-HA-RBR-30C7, pcDNA3.1-HA-HECT-28E11, pcDNA3.1-HA-RBR-28E 11) were co-transfected with pcDNA3.1-Flag-ISG15, respectively, into HeLa cells, protein samples were harvested after 48h and Western bolt assays were performed using eIF4E2 antibody assays.
FIG. 4 shows the results of the chimeric HECT-30C7 activation of eIF4E2ISGylation according to the present invention. (A) The HECT domain of E3 ligase HERC and its active center Cys994. Mutation of Cys to Ala inhibits its ability to transmit ISG 15. (B) Chimeric HECT-30C7 activates the ISGylation modification of eIF4E 2. The chimeras pcDNA3.1-HA-HECT-30C7, pcDNA3.1-HA-HECT (C994A) -30C7 and pcDNA3.1-HA-HECT-BV025 were co-transformed or single-transformed with pcDNA3.1-Flag-ISG15, respectively, into HeLa cells, and after 48 hours protein samples were collected and Western felt detection was performed using eIF4E2 antibody detection. (C) pcDNA3.1-HECT-30C7, pcDNA3.1-HA-eIF4E2 and pcDNA3.1-Flag-ISG15 were co-transfected into 293T cells, anti-Flag co-immunoprecipitation was performed on the cells after 48h, western-felt detection was performed on the obtained samples, and HECT-BV025 was used as a control.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Proteolysis targeting chimera (PROTAC) is a technology developed in recent years to target protein degradation. The PROTAC molecule consists essentially of two parts, a ligand (mainly a small molecule inhibitor) capable of binding to the target protein and E3 ubiquitin ligase, and when the ligand binds to the target protein, ubiquitination of the target protein is induced by recruiting ubiquitin by the E3 ubiquitin ligase linked to the ligand, thereby mediating degradation of the target protein (Li et al 2020). In addition, researchers have further developed the Bio-PROTAC technology by directly replacing the substrate recognition domain of the E3 ligase with a small peptide fragment or small molecule protein that specifically binds to the target protein, thereby expanding the range of applications of the PROTAC technology (Lim et al 2020). ISGylation is similar to the ubiquitination modification process in that isgyl modification covalently binds ISG15 to the target protein via E3 ligase. Since engineering an E3 ubiquitin ligase is capable of mediating specific site ubiquitination, engineering the substrate recognition domain of an E3 ligase for ISGylation based on similar principles should also be possible to target activation of ISGylation modification. We have therefore engineered the ISGylation E3 ligase: novel E3 chimeric enzyme is formed by fusion expression of a functional domain (a domain catalyzing transfer of ISG15 to a target protein) in an ISGylating E3 ligase and a nanobody, and the chimeric body can realize ISGylating activation specific to the target protein by utilizing high specificity and high affinity of the nanobody.
In the following examples, the biological materials involved are as follows:
1) Experimental strains
Coli DH5a and EBY100 were laboratory-preserved strains.
2) Cell lines
3) Vectors and plasmids
Eukaryotic expression vectors pcDNA3.1, pcDNA3.1-3 xFlag, pcDNA3.1-HA and yeast protein expression vector pNACP are all preserved in a laboratory, and other plasmids are all self-constructed.
Example 1 Targeted screening of eIF4E2 nanobodies
Construction of nanobody library: at the beginning of the experiment we obtained the eIF4E2 targeting nanobodies 28A1 and 30G11 by phage display technology. On this basis, we designed NNK degenerate primers and introduced saturation mutagenesis into the CDR regions by PCR techniques. And then, by utilizing the high homologous recombination property of the yeast, the mutation library and the linearized surface display carrier pNACP are jointly and electrically transformed into Saccharomyces cerevisiae EBY100 to obtain two small yeast display libraries (28 library-yeast and 30 library-yeast) containing CDR region mutations, so that yeast display screening is performed.
Screening of yeast libraries first the library is induced to express so that nanobodies can be displayed on the surface of yeast cells. The antigen BSA-peptide (BSA coupled eIF4E2N, C end polypeptide sequence) was then mixed with anti-BSA (murine) and incubated with rotation at room temperature. After the incubation of the antigen part is completed, the yeast cells after induced expression and anti-Myc (rabbit source) are added, and the yeast cells with eIF4E2 nanobody are rotated and incubated at room temperature, so that the yeast cells with eIF4E2 nanobody are fully combined with the antigen. The BSA was then incubated with FITC (showing the binding efficiency of antigen to nanobody) and Myc-tagged Alexa647 (showing the display efficiency of nanobody). After the secondary antibody incubation is completed, yeast cells with double fluorescence can be selected through a flow cell sorter, and the nano antibody carried by the obtained double fluorescence yeast cells is the nano antibody capable of being specifically combined with the antigen.
The enrichment rates of 28 library-yeast and 30 library-yeast were continuously increased in 3 rounds of sorting to 43% and 60.9% respectively (A, B in FIG. 1) using CDR region saturation mutagenesis nanobody yeast display libraries. The sequencing of the nano antibody with the positive rate of ten in 30 library-yeast has 5 successful sequencing, wherein 3 of the 5 sequences are the same sequence, namely the sequence of the 30C7 clone is enriched, and the 30C7 clone with the highest positive rate in 30 library-yeast is also obtained. 9 sequences were successfully sequenced in 28 library-year, with the highest positive rate for the 28E11 clone, and the results after sequence deduplication are shown in Table 1, where WT represents the wild type. We therefore selected nanobodies 28E11 (targeting eIF4E 2C-terminus) and 30C7 (targeting eIF4E 2N-terminus) for subsequent experiments. Clones with a positive rate of 10 a in the 28 library-year and 30 library-year 96 Kong Banliu format were selected for sequencing and aligned with the WT sequence, and the sequencing results showed that mutations occurred predominantly in the CDR3 region.
Table 1: positive rate
The sequences shown in Table 1 are as follows.
>28WT(SEQ ID NO:1):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISSGGSITNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYPHRYGHYWGQGTQVTVSS
>28E11(SEQ ID NO:2):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISSGGSITNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYHSLYYGYWGQGTQVTVSS
>28B1(SEQ ID NO:3):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISSGGSITNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYPPLYCHYWGQGTQVTVSS
>28C4(SEQ ID NO:4):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISCGGAITNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYLPRYGSYWGQGTQVTVSS
>28F12(SEQ ID NO:5):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISCGAGITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYYSRHYGYWGQGTQVTVSS
>28F11(SEQ ID NO:6):
QVQLQESGGGLVQAGGSLRLSCAASGRTSSSYAMGWFRQAPGKEREFVAAISCGAAITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYYSRHYGYWGHGTQGTVSS
>28F5(SEQ ID NO:7):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISCAGAITNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYLRRYGSSYDYWGQGTQVTVSS
>28A9(SEQ ID NO:8):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISCGGSITNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAHYLPHHYDYWGQGTQVTVSS
>28E10(SEQ ID NO:9):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISCAGSSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAHSPDLYYDYWGHGTQGTVSS
>28E3(SEQ ID NO:10):
QVQLQESGGGLVQAGGSLRLSCAASGCTSSSYAMGWFRQAPGKEREFVAAISCDSGITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARYYSNPYGYWGQGTQVTVSS
>30C7(SEQ ID NO:11):
QVQLQESGGGLVQAGGSLRLSCAASGYTFSSNVMGWFRQAPGKEREFVAAINSGGGRTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAYGRANSSYNYGYWGQGTQVTVSS
>30F8(SEQ ID NO:12):
QVQLQESGGGLVQAGGSLRLSCAASGYTNSRYYMGWFRQAPGKEGEFVAAISRSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAASRSSSSSLYDYWGQGTQVTVSS
>30WT(SEQ ID NO:13):
QVQLQESGGGLVQAGGSLRLSCAASGRTFSRYAMGWFRQAPGKEREFVAAISRGGGRTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARRSGRRGSSLLRYD YWGQGTQVTVSS
Example 2eIF4E2 ISGylation modified verification
1) Constructing a bio-PROTAC system by replacing a substrate recognition domain of E3 ubiquitin ligase with a high-affinity eIF4E2 nanobody, degrading eIF4E2 in cells, adding LPS to activate eIF4E2ISGylation modification after 48h transfection, and verifying migration bands after eIF4E2ISGylation modification;
2) And (3) transferring siRNA targeting eIF4E2 into cells, and adding LPS to activate eIF4E2ISGylation modification after 36h transfection to verify migration bands after eIF4E2ISGylation modification occurs.
ISGylation may occur at the K134 and K222 sites of eIF4E2 (FIG. 2A). LPS (lipopolysaccharide) is a strong activator of immune cells and can be used to treat cells that stimulate IFN expression, thereby activating the onset of modification of the related protein ISGylation. To verify ISGylation modification of eIF4E2 we treated 293T cells with LPS, SDS dissociated the cells and Western felt detection with antibodies to eIF4E 2. We found that the LPS treated group showed a clearly activated band at approximately 45kd compared to the control group (fig. 2B lane 2). To further demonstrate that this activated band may be a migration band after modification of eIF4E2, we designed siRNA to lower its mRNA level for eIF4E2 and added LPS 48h after eIF4E2 transfection of siRNA. Protein samples were harvested 6h after LPS treatment and Western felt detection with an antibody to eIF4E 2. The results are shown in FIG. 2B: the siRNA targeting eIF4E2 reduces the expression level of the migration bands occurring after eIF4E2 background and LPS treatment.
We also performed similar experiments in BT549 cells (breast cancer cells), applying the Bio-PROTAC technique to target degradation of eIF4E2 at the protein level, and adding LPS 48h after transfection of PROTAC. Protein samples were harvested 6h after LPS treatment and Western felt detection with an antibody to eIF4E 2. We found that the activated bands appeared at the same positions in the LPS-treated BT549 cells (FIG. 2C lane 2), and that PROTAC-30C7 and PROTAC-28E11, which target degradation of eIF4E2 protein levels, reduced levels of eIF4E2 background and migration bands that appeared after LPS treatment, with higher degradation efficiency of PROTAC-30C7 (FIG. 2C), indicating that nanobody 30C7 may be more suitable for targeting the native conformation of eIF4E 2. In different cell lines, the migration band of eIF4E2 activated by LPS could be reduced by siRNA and PROTAC targeting eIF4E2, both different ways yielding the same result. We therefore speculate that eIF4E2 migrates after ISGylation modification, with a migration band occurring at about 45 kd.
Example 3 construction of E3 ligase chimeras targeting eIF4E2ISGylation modification
The ISG 15-transmitting domain in the ISGylation E3 ligase was linked by molecular cloning to a nanobody that specifically recognized eIF4E 2.
HERC5 is a relatively common ISGylation E3 ligase. HHARI is the ubiquitin E3 ligase of eIF4E 2. The structure of these two E3 ligases mainly includes: the functional domain, substrate recognition domain and other ancillary domains of ISG15 are transferred. The HECT domain functions to deliver ISG15 in HERC5 and the RBR domain functions to deliver ISG15 in HHARI (FIG. 3A). For construction of eIF4E 2-targeting E3 ligase chimera we retained HECT in the HERC5 and HHARI E3 ligase with the RING1-IBR-RING2 (RBR) domain and linked the HECT domain to nanobody 30C7 targeting eIF4E 2N-terminus and nanobody 28E11 targeting eIF4E 2C-terminus, respectively, by a short linker, as well as the RBR domain to nanobodies 30C7 and 28E11, respectively (fig. 3B). The 4 sets of E3 chimeric fragments were then constructed onto mammalian cell expression vector pcdna3.1, yielding 4 sets of plasmids: pcDNA3.1-HA-HECT-30C7, pcDNA3.1-HA-RBR-30C7, pcDNA3.1-HA-HECT-28E11, pcDNA3.1-HA-RBR-28E11.
The working principle of the novel E3 ligase chimera is as follows: the chimera can utilize nanobody specific targeting to bring the E3 ligase of ISGylation into proximity with the target protein, facilitating covalent attachment of ISG15 to the target protein, thereby specifically mediating ISGylation modification of the protein of interest (fig. 3C). To initially verify the feasibility of activation of eIF4E2ISGylation modification of 4 sets of nanobody-E3 ligase chimeras, we transfected pcdna3.1-Flag-ISG15 with plasmids of these four sets of chimeras, respectively, in Hela cells, and after 48h of transfection, cell harvest samples were lysed with SDS for Western felt detection with antibodies to eIF4E 2. The results show that chimeric HECT-30C7 may be effective in activating the ISGylation modification of eIF4E2 (FIG. 3D).
Example 4 chimeric activation of eIF4E2ISGylation
The activation of eIF4E2ISGylation by the chimera was further verified by constructing the E3 ligase mutant with negative nanobody control.
Cys994 located in the HECT domain is the E3 ligase HERC5 active site (FIG. 4A). Cys994 is critical for the delivery of ISG15, and after mutation to alanine, its function of delivering ISG15 is reduced or lost. In addition BV025 is a nanobody reported in the literature that does not recognize any target protein, and is often used as a negative control for nanobodies. We have thus constructed HECT (C994A) mutant and BV 025E 3 chimeric as controls to further verify HECT-30C7 activation of eIF4E2ISGylation modification. And respectively transferring the constructed pcDNA3.1-HA-HECT-30C7, pcDNA3.1-HA-HECT (C994A) -30C7 and pcDNA3.1-HA-HECT-BV025 plasmids and pcDNA3.1-Flag-ISG15 into Hela cells, and collecting protein samples after 48 hours for Western felt detection. The results are shown in fig. 4C: the C994A mutation of HECT inhibited activation of the migration band after ISGylation modification of eIF4E2 relative to HECT-30C7 of WT, and the activation of the eIF4E2ISGylation modification by either chimeric HECT-BV025 or singly-transferred Flag-ISG15 was not apparent, indicating that chimeric HECT-30C7 might be specific for ISGylation modification of eIF4E 2.
We also performed CO-immunoprecipitation (CO-IP) to verify the activation of the eIF4E2ISGylation modification by the chimera HECT-30C 7. For IP experiments we constructed the sequences HECT-30C7 and HECT-BV025 on the mammalian expression vector pcDNA3.1, respectively, along with the HA-tagged eIF4E2 and Flag-tagged ISG15 pcDNA3.1 plasmids. The pcDNA3.1-HECT-30C7 was then co-transferred into 293T cells with pcDNA3.1-HA-eIF4E2 and pcDNA3.1-Flag-ISG15 plasmids, and the cell lysates were subjected to anti-Flag co-immunoprecipitation after 48h of transfection. If the chimeric HECT-30C7 activates the ISGylation modification of eIF4E2, flag-ISG15 will be covalently bound to the modification site of HA-eIF4E2, then when we pull Flag-ISG15 with the tags of Flag, we will pull HA-eIF4E2 down together, at which time we can detect the HA signal in IP samples by Western felt. The experimental results are shown in fig. 4C: HA signal was detected in IP samples co-transfected HECT-30C7 with HA-eIF4E2 and Flag-ISG15, and the band size of HA was also around 45kd, consistent with the eIF4E2 migration band size detected in the previous LPS-treated group, while no HA signal was detected in control HECT-BV 025.
Conclusion: among the four groups of chimeras, chimera HECT-30C7 activated eIF4E2ISGylation modification was the best. Neither the C994A mutant of HECT nor the nanobody negative control BV025 activated eIF4E2ISGylation relative to the chimeric HECT-30C 7. IP results showed that the chimeric HECT-30C7 activated eIF4E2 ISGylation.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (4)
1. The nano antibody targeting eIF4E2is characterized by having an amino acid sequence shown in SEQ ID NO:11.
2. The E3 ligase chimera modified by targeting eIF4E2ISGylation sequentially comprises the nanobody of claim 1, a linker and a connecting domain fragment connected with the nanobody; the linking domain fragment is the HECT domain in HERC5 that delivers ISG15 function.
3. An expression vector comprising the E3 ligase chimera of claim 2.
4. A cell transfected with the expression vector of claim 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310843861.5A CN116854817B (en) | 2023-07-10 | 2023-07-10 | Nano antibody targeting eIF4E2, E3 ligase chimeric and application thereof in ISGylation activation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310843861.5A CN116854817B (en) | 2023-07-10 | 2023-07-10 | Nano antibody targeting eIF4E2, E3 ligase chimeric and application thereof in ISGylation activation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116854817A CN116854817A (en) | 2023-10-10 |
CN116854817B true CN116854817B (en) | 2024-03-08 |
Family
ID=88218595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310843861.5A Active CN116854817B (en) | 2023-07-10 | 2023-07-10 | Nano antibody targeting eIF4E2, E3 ligase chimeric and application thereof in ISGylation activation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116854817B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018184003A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon |
CN109839508A (en) * | 2019-01-30 | 2019-06-04 | 华中农业大学 | Application of the Rbm24-S181 site phosphorylation as stress class disease and the marker of related cardiac conditions medication |
CN110687283A (en) * | 2019-08-26 | 2020-01-14 | 中国医学科学院肿瘤医院 | Use of autoantibodies for diagnosis and/or treatment of tumors |
-
2023
- 2023-07-10 CN CN202310843861.5A patent/CN116854817B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018184003A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon |
CN109839508A (en) * | 2019-01-30 | 2019-06-04 | 华中农业大学 | Application of the Rbm24-S181 site phosphorylation as stress class disease and the marker of related cardiac conditions medication |
CN110687283A (en) * | 2019-08-26 | 2020-01-14 | 中国医学科学院肿瘤医院 | Use of autoantibodies for diagnosis and/or treatment of tumors |
Non-Patent Citations (2)
Title |
---|
eIF4E2调控RBM24磷酸化介导心脏适应压力;杨鹤;中国博士学位论文全文数据库医药卫生科技辑(第2期);第91页3.6.1 筛选激活RBM24 S181磷酸化纳米抗体 * |
P58IPK通过PERK/eIF2α通路调控猪圆环病毒2型所诱导的细胞自噬;杨了寒等;畜牧兽医学报;第48卷(第11期);第2125-2134页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116854817A (en) | 2023-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sherpa et al. | How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini | |
US20090220455A1 (en) | Pharmaceutical compositions comprising elp fusion proteins | |
CN111712574B (en) | Fusion proteins | |
KR20210053228A (en) | An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof | |
KR102067760B1 (en) | Protein complex for intracellular delivery and uses thereof | |
JP2021515582A (en) | Extensive proteome editing with engineered bacterial ubiquitin ligase mimics | |
KR20130010461A (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
CN109564215A (en) | Method for being summarized with variant SH2 structural domain protein tyrosine phosphorylation | |
WO2018184267A1 (en) | Mrna-encoded nanobody and application thereof | |
CN111569065B (en) | Composition for targeted ubiquitination degradation of endogenous Survivin of cells by using nano antibody and application of composition | |
CN116854817B (en) | Nano antibody targeting eIF4E2, E3 ligase chimeric and application thereof in ISGylation activation | |
Szyszka et al. | Molecular display on protein nanocompartments: design strategies and systems applications | |
CN108179149B (en) | S100B mutant and application thereof | |
KR101587622B1 (en) | Novel Polypeptide Binding with Ectodomain of Human Epidermal Growth Factor Receptor | |
CN104844691A (en) | Sox2 protein peptide aptamer and authenticating method thereof | |
US10287342B2 (en) | Polypeptide for binding to complement protein C5A, and use of same | |
CN102033057A (en) | Antibody test method based on multi-function polymer and fluorescent resonance energy transfer | |
CN112955184A (en) | Programmable immune cell receptor complex system | |
CN113234152B (en) | Programmed death receptor-ligand 1 (PD-L1) specific binding polypeptide and application thereof | |
CN104031134A (en) | Vector protein for gene therapy as well as preparation method and application of vector protein | |
CN114457048A (en) | Protein biotin ligase and adjacent protein labeling system and application thereof | |
CN104672333A (en) | Human-derived CTLA4 fusion protein and its preparation method and use | |
CN110845596A (en) | Mutant xSUMO and related products | |
CN116178538B (en) | Nanometer antibody targeting heat shock protein 70 and preparation method and application thereof | |
WO2012082069A1 (en) | Protein aptamers based on unstructured scaffold proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |